Review



cchfv hoti np peptides  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation cchfv hoti np peptides
    On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) <t>IFNу</t> <t>ELISpot</t> shown as cumulative responses against peptides spanning the entire <t>CCHFV</t> NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.
    Cchfv Hoti Np Peptides, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cchfv hoti np peptides/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cchfv hoti np peptides - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21"

    Article Title: Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21

    Journal: Nature Communications

    doi: 10.1038/s41467-024-53362-7

    On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) IFNу ELISpot shown as cumulative responses against peptides spanning the entire CCHFV NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.
    Figure Legend Snippet: On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) IFNу ELISpot shown as cumulative responses against peptides spanning the entire CCHFV NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.

    Techniques Used: Infection, Enzyme-linked Immunospot, Flow Cytometry, Standard Deviation



    Similar Products

    cchfv hoti np peptides  (GenScript corporation)
    90
    GenScript corporation cchfv hoti np peptides
    On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) <t>IFNу</t> <t>ELISpot</t> shown as cumulative responses against peptides spanning the entire <t>CCHFV</t> NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.
    Cchfv Hoti Np Peptides, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cchfv hoti np peptides/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cchfv hoti np peptides - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    cchfv hoti np  (GenScript corporation)
    90
    GenScript corporation cchfv hoti np
    On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) <t>IFNу</t> <t>ELISpot</t> shown as cumulative responses against peptides spanning the entire <t>CCHFV</t> NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.
    Cchfv Hoti Np, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cchfv hoti np/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cchfv hoti np - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) IFNу ELISpot shown as cumulative responses against peptides spanning the entire CCHFV NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.

    Journal: Nature Communications

    Article Title: Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21

    doi: 10.1038/s41467-024-53362-7

    Figure Lengend Snippet: On D5 p.i., groups of mice ( N = 6) from Fig. were euthanized and evaluated for cellular immune responses to infection via ( a ) IFNу ELISpot shown as cumulative responses against peptides spanning the entire CCHFV NP (SFC: spot forming cells). For T-cell depletion study, WT C57BL6/J mice were ( b ) vaccinated with Sham or repNP RNA on day −28 relative to lethal CCHFV challenge. On days −5, −2, and +5 relative to CCHFV challenge, mice were treated with isotype or αCD4 and αCD8 antibody to deplete mice of T-cell populations. On D0, groups of mice were evaluated for immunological response to vaccine or treated with MAR1−5A3 antibody and infected with a lethal dose of 100 TCID 50 CCHFV strain UG3010. Mice ( N = 8) were ( c ) weighed daily and monitored for ( d ) survival until day 14 p.i., On D5 p.i., groups of mice ( N = 6) were evaluated for ( e ) depletion of CD4+ and CD8 + T-cell populations via Flow Cytometry. Antibody treatment achieved a 96.3% depletion of CD4 + T-cells and 98.5% depletion of CD8 + T-cells. In the second study, groups of WT C57BL6/J and CD8 −/− mice were vaccinated and infected as above. Mice ( N = 8) were ( f ) weighed daily and monitored for ( g ) survival until day 14 p.i. Dashed lines indicate limit of detection. Data shown as mean plus standard deviation. Significance was calculated using one-way ANOVA; ns P > 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Exact p -values: ( d ) both P = 0.0002, ( g ) both P = 0.0002.

    Article Snippet: To measure CCHFV-specific T-cell responses, an IFNγ ELISpot kit (ImmunoSpot) was used with peptides spanning the entire CCHFV Hoti NP (GenScript).

    Techniques: Infection, Enzyme-linked Immunospot, Flow Cytometry, Standard Deviation